Veeva Announces Fiscal 2024 Third Quarter Results

Total Revenues of $616.5M, up 12% Year Over Year; Subscription Services Revenues of $494.9M, up 12% Year Over Year

PLEASANTON, Calif., Dec. 6, 2023 /PRNewswire/ — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2023.

“It was another strong quarter as we advance the industry toward more efficient and effective ways of working, from drug development through commercialization,” said CEO Peter Gassner. “We announced a number of new innovations, expanded in existing markets, and continued progress in newer areas like Vault CRM, positioning us well for durable, profitable growth for years to come.”

Fiscal 2024 Third Quarter Results:

Revenues: Total revenues for the third quarter were $616.5 million, up from $552.4 million one year ago, an increase of 12% year over year. Subscription services revenues for the third quarter were $494.9 million, up from $441.6 million one year ago, an increase of 12% year over year.
Operating Income and Non-GAAP Operating Income(1): Third quarter operating income was $128.5 million, compared to $121.4 million one year ago, an increase of 6% year over year. Non-GAAP operating income for the third quarter was $234.6 million, compared to $219.5 million one year ago, an increase of 7% year over year.
Net Income and Non-GAAP Net Income(1): Third quarter net income was $135.2 million, compared to $108.5 million one year ago, an increase of 25% year over year. Non-GAAP net income for the third quarter was $218.7 million, compared to $183.2 million one year ago, an increase of 19% year over year.
Net Income per Share and Non-GAAP Net Income per Share(1): For the third quarter, fully diluted net income per share was $0.83, compared to $0.67 one year ago, while non-GAAP fully diluted net income per share was $1.34, compared to $1.13 one year ago.
Customer Contracting Change: The previously announced customer contracting change that standardized termination for convenience (TFC) rights in our master subscription agreements went into effect on February 1, 2023. This resulted in a change in the timing of revenue for certain customer contracts to which a TFC right was added and reduced revenues, operating income and non-GAAP operating income, and net income and non-GAAP net income in the third quarter.

“We are managing the business well and continue to track towards our longer term targets,” said CFO Brent Bowman. “We’re in the early innings of a large and growing opportunity, and we believe our software, data, and high value services will enable us to drive growth and profitability through 2030 and beyond.”

Recent Highlights:

Commercial Innovation Drives Continued Leadership – Veeva announced new innovations coming in Veeva Commercial Cloud including Marketing Automation for campaign management and Patient CRM to manage sensitive patient information and workflows. Veeva also crossed significant milestones for Vault CRM – including the first customer live – as it looks ahead to delivering the next-generation of CRM for life sciences. Two top 20 biopharmas also committed to Vault CRM globally as the path to commercial innovation. 
Delivering the Modern Data Platform for the Industry – Veeva Data Cloud provides the industry a modern alternative to legacy data, all on a common data architecture. This fueled strong progress in the quarter with a record 13 new brands for Compass, two top 20 biopharma wins for Link, and the recent announcement of a second top 20 biopharma that will roll out OpenData globally. 
Establishing the Technology Foundation for Drug Development – Momentum continued in the significant long-term opportunity for Veeva Development Cloud. In the quarter, the company saw further adoption across all product areas, including 24 customer wins across clinical, 23 for quality, and 15 in regulatory. Development Cloud also continues to expand as new products were announced in clinical and quality, two of Veeva’s largest opportunities in R&D.

Financial Outlook:

Veeva is providing guidance for its fiscal fourth quarter ending January 31, 2024 as follows:

Total revenues between $620 and $622 million.
Non-GAAP operating income of about $227 million(2).
Non-GAAP fully diluted net income per share of approximately $1.30(2).

Veeva is providing updated guidance for its fiscal year ending January 31, 2024 as follows:

Total revenues between $2,353 and $2,355 million.
Non-GAAP operating income of about $830 million(2).
Non-GAAP fully diluted net income per share of approximately $4.76(2).

Veeva is reiterating guidance for its fiscal year ending January 31, 2025 for the following metrics:

Total revenues of at least $2,750 million.
Non-GAAP operating income of at least $1,000 million(2).

Conference Call InformationPrepared remarks and an investor presentation providing additional information and analysis can be found on Veeva’s investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, December 6, 2023, and a replay of the call will be available on Veeva’s investor relations website.

(1)

This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled “Non-GAAP Financial Measures” and the tables entitled “Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.

(2)

Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the fourth fiscal quarter ending January 31, 2024, the fiscal year ending January 31, 2024, or the fiscal year ending January 31, 2025, because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking StatementsThis release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of December 6, 2023, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, security, or privacy of our products, competitive factors, customer decisions and priorities, events that impact the life sciences industry, general macroeconomic and geopolitical events (including inflationary pressures, changes in interest rates, currency exchange fluctuations, changes in applicable laws and regulations, and impacts related to Russia’s invasion of Ukraine and the Israel-Hamas conflict), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 38 and 39 in our filing on Form 10-Q for the period ended July 31, 2023 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:Gunnar Hansen
Veeva Systems Inc.
267-460-5839
[email protected]

Media Contact:Maria Scurry
Veeva Systems Inc.
781-366-7617
[email protected]

VEEVA SYSTEMS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)

October 31,
2023

January 31,
2023

Assets

Current assets:

Cash and cash equivalents

$         743,712

$         886,465

Short-term investments

3,198,570

2,216,163

Accounts receivable, net

255,504

703,055

Unbilled accounts receivable

44,837

82,174

Prepaid expenses and other current assets

93,135

81,456

Total current assets

4,335,758

3,969,313

Property and equipment, net

57,597

49,817

Deferred costs, net

19,733

31,825

Lease right-of-use assets

48,139

55,336

Goodwill

439,877

439,877

Intangible assets, net

67,919

82,476

Deferred income taxes

218,348

136,697

Other long-term assets

38,401

38,955

Total assets

$      5,225,772

$      4,804,296

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$           36,236

$           41,678

Accrued compensation and benefits

38,430

44,282

Accrued expenses and other current liabilities

32,921

35,306

Income tax payable

6,560

4,946

Deferred revenue

644,463

869,285

Lease liabilities

9,640

11,306

Total current liabilities

768,250

1,006,803

Deferred income taxes

1,145

1,492

Lease liabilities, noncurrent

48,026

49,670

Other long-term liabilities

28,578

30,079

Total liabilities

845,999

1,088,044

Stockholders’ equity:

Class A common stock

2

2

Class B common stock

Additional paid-in capital

1,824,250

1,532,627

Accumulated other comprehensive loss

(37,538)

(31,129)

Retained earnings

2,593,059

2,214,752

Total stockholders’ equity

4,379,773

3,716,252

Total liabilities and stockholders’ equity

$      5,225,772

$      4,804,296

VEEVA SYSTEMS INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands, except per share data)(Unaudited)

Three months ended
October 31,

Nine months ended
October 31,

2023

2022

2023

2022

Revenues:

Subscription services(3)

$     494,912

$     441,569

$  1,380,095

$  1,272,850

Professional services and other(4)

121,593

110,782

352,960

318,821

Total revenues

616,505

552,351

1,733,055

1,591,671

Cost of revenues(5):

Cost of subscription services

74,435

65,734

213,179

188,722

Cost of professional services and other

93,247

88,173

290,184

256,369

Total cost of revenues

167,682

153,907

503,363

445,091

Gross profit

448,823

398,444

1,229,692

1,146,580

Operating expenses(5):

Research and development

161,278

130,257

465,466

377,740

Sales and marketing

96,773

93,910

282,269

259,642

General and administrative

62,283

52,873

187,887

159,030

Total operating expenses

320,334

277,040

935,622

796,412

Operating income

128,489

121,404

294,070

350,168

Other income, net

42,187

12,458

111,260

23,565

Income before income taxes

170,676

133,862

405,330

373,733

Income tax provision 

35,518

25,405

27,023

74,560

Net income

$     135,158

$     108,457

$     378,307

$     299,173

Net income per share:

Basic

$           0.84

$           0.70

$           2.36

$           1.93

Diluted

$           0.83

$           0.67

$           2.32

$           1.84

Weighted-average shares used to compute net income per share:

Basic

160,768

155,392

160,344

154,958

Diluted

163,761

162,295

163,129

162,189

Other comprehensive income:

Net change in unrealized loss on available-for-sale investments

$       (2,637)

$     (17,499)

$       (6,100)

$     (30,722)

Net change in cumulative foreign currency translation loss

(518)

(808)

(309)

(2,962)

Comprehensive income

$     132,003

$       90,150

$     371,898

$     265,489

(3) Includes subscription services revenues from the following product areas:

Veeva Commercial Solutions

$     251,167

$     239,276

$     733,921

$     703,356

Veeva R&D Solutions

243,745

202,293

646,174

569,494

Total subscription services

$     494,912

$     441,569

$  1,380,095

$  1,272,850

(4) Includes professional services and other revenues from the following product areas:

Veeva Commercial Solutions

$       47,899

$       45,283

$     140,082

$     133,027

Veeva R&D Solutions

73,694

65,499

212,878

185,794

Total professional services and other

$     121,593

$     110,782

$     352,960

$     318,821

(5) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription services

$         1,604

$         1,636

$         4,857

$         4,606

Cost of professional services and other

12,943

13,227

39,881

37,035

Research and development

45,711

37,415

129,909

102,139

Sales and marketing

23,460

23,576

67,084

64,500

General and administrative

17,508

17,333

53,109

48,083

Total stock-based compensation

$     101,226

$       93,187

$     294,840

$     256,363

VEEVA SYSTEMS INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited)

Three months ended
October 31,

Nine months ended
October 31,

2023

2022

2023

2022

Cash flows from operating activities

Net income

$     135,158

$     108,457

$     378,307

$     299,173

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

8,364

7,157

24,000

21,443

Reduction of operating lease right-of-use assets

2,860

3,094

8,885

9,062

Accretion of discount on short-term investments

(8,515)

(1,565)

(19,298)

(1,016)

Stock-based compensation

101,226

93,187

294,840

256,363

Amortization of deferred costs

3,542

5,378

12,843

17,107

Deferred income taxes

(33,405)

(31,056)

(80,132)

(84,369)

Loss on foreign currency from mark-to-market derivative

1,388

7

841

1,193

Bad debt expense

134

1,089

630

1,210

Changes in operating assets and liabilities:

Accounts receivable

123,428

69,272

446,921

387,066

Unbilled accounts receivable

(7,296)

(4,307)

37,337

(18,819)

Deferred costs

(812)

(5,376)

(751)

(11,876)

Other current and long-term assets

(16,051)

7,326

(6,806)

(3,750)

Accounts payable

(13,556)

10,002

(5,502)

20,663

Accrued expenses and other current liabilities

(8,443)

5,465

(9,572)

2,654

Income taxes payable

(17,583)

49,323

1,614

46,705

Deferred revenue

(192,037)

(174,544)

(228,120)

(222,013)

Operating lease liabilities

27

(2,624)

(4,263)

(7,736)

Other long-term liabilities

4,169

2,375

1,796

4,013

Net cash provided by operating activities

82,598

142,660

853,570

717,073

Cash flows from investing activities

Purchases of short-term investments

(541,502)

(710,833)

(2,142,068)

(1,716,250)

Maturities and sales of short-term investments

474,088

310,713

1,170,881

757,434

Long-term assets

(5,910)

(5,609)

(18,461)

(9,605)

Net cash used in investing activities

(73,324)

(405,729)

(989,648)

(968,421)

Cash flows from financing activities

Proceeds from exercise of common stock options

13,956

4,575

52,184

30,116

Taxes paid related to net share settlement of equity awards

(20,845)

(15,118)

(57,888)

(47,251)

Net cash used in financing activities

(6,889)

(10,543)

(5,704)

(17,135)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(1,282)

(1,475)

(973)

(4,398)

Net change in cash, cash equivalents, and restricted cash

1,103

(275,087)

(142,755)

(272,881)

Cash, cash equivalents, and restricted cash at beginning of period

745,792

1,143,431

889,650

1,141,225

Cash, cash equivalents, and restricted cash at end of period

$     746,895

$     868,344

$     746,895

$     868,344

Supplemental disclosures of other cash flow information:

Excess tax benefits from employee stock plans

$         3,275

$            888

$       68,575

$         5,981

Non-GAAP Financial MeasuresIn Veeva’s public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefits. Excess tax benefits from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. For example, excess tax benefits for the quarters ended January 31 and April 30, 2023 were higher than normal primarily due to our Chief Executive Officer’s exercise of stock options in connection with a previously announced trading plan. Because these fluctuations are not directly related to our business operations, Veeva excludes excess tax benefits for its internal management reporting processes. Veeva management also finds it useful to exclude excess tax benefits when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits, Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies.
Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva’s management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies.
Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva’s management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva’s revenues earned during the periods presented and will contribute to Veeva’s future period revenues as well.
Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva’s management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(Dollars in thousands)
(Unaudited)

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: 

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended
October 31,

Nine months ended
October 31,

2023

2022

2023

2022

Net cash provided by operating activities on a GAAP basis

$    82,598

$  142,660

$  853,570

$  717,073

Excess tax benefits from employee stock plans

(3,275)

(888)

(68,575)

(5,981)

Net cash provided by operating activities on a non-GAAP basis

$    79,323

$  141,772

$  784,995

$  711,092

Net cash used in investing activities on a GAAP basis

$  (73,324)

$  (405,729)

$ (989,648)

$ (968,421)

Net cash used in financing activities on a GAAP basis

$    (6,889)

$  (10,543)

$    (5,704)

$  (17,135)

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended
October 31,

Nine months ended
October 31,

2023

2022

2023

2022

Cost of subscription services revenues on a GAAP basis

$    74,435

$    65,734

$  213,179

$  188,722

Stock-based compensation expense

(1,604)

(1,636)

(4,857)

(4,606)

Amortization of purchased intangibles

(1,126)

(1,126)

(3,343)

(3,342)

Cost of subscription services revenues on a non-GAAP basis

$    71,705

$    62,972

$  204,979

$  180,774

Gross margin on subscription services revenues on a GAAP basis

85.0 %

85.1 %

84.6 %

85.2 %

Stock-based compensation expense

0.3

0.4

0.3

0.3

Amortization of purchased intangibles

0.2

0.2

0.2

0.3

Gross margin on subscription services revenues on a non-GAAP basis

85.5 %

85.7 %

85.1 %

85.8 %

Cost of professional services and other revenues on a GAAP basis

$    93,247

$    88,173

$  290,184

$  256,369

Stock-based compensation expense

(12,943)

(13,227)

(39,881)

(37,035)

Amortization of purchased intangibles

(139)

(139)

(411)

(411)

Cost of professional services and other revenues on a non-GAAP basis

$    80,165

$    74,807

$  249,892

$  218,923

Gross margin on professional services and other revenues on a GAAP basis

23.3 %

20.4 %

17.8 %

19.6 %

Stock-based compensation expense

10.6

11.9

11.3

11.6

Amortization of purchased intangibles

0.2

0.2

0.1

0.1

Gross margin on professional services and other revenues on a non-GAAP basis

34.1 %

32.5 %

29.2 %

31.3 %

Gross profit on a GAAP basis

$  448,823

$  398,444

$  1,229,692

$  1,146,580

Stock-based compensation expense

14,547

14,863

44,738

41,641

Amortization of purchased intangibles

1,265

1,265

3,754

3,754

Gross profit on a non-GAAP basis

$  464,635

$  414,572

$  1,278,184

$  1,191,975

Gross margin on total revenues on a GAAP basis

72.8 %

72.1 %

71.0 %

72.0 %

Stock-based compensation expense

2.4

2.7

2.6

2.6

Amortization of purchased intangibles

0.2

0.3

0.2

0.3

Gross margin on total revenues on a non-GAAP basis

75.4 %

75.1 %

73.8 %

74.9 %

Research and development expense on a GAAP basis

$  161,278

$  130,257

$  465,466

$  377,740

Stock-based compensation expense

(45,711)

(37,415)

(129,909)

(102,139)

Amortization of purchased intangibles

(29)

(29)

(85)

(85)

Research and development expense on a non-GAAP basis

$  115,538

$    92,813

$  335,472

$  275,516

Three months ended
October 31,

Nine months ended
October 31,

2023

2022

2023

2022

Sales and marketing expense on a GAAP basis

$    96,773

$    93,910

$  282,269

$  259,642

Stock-based compensation expense

(23,460)

(23,576)

(67,084)

(64,500)

Amortization of purchased intangibles

(3,555)

(3,555)

(10,550)

(10,550)

Sales and marketing expense on a non-GAAP basis

$    69,758

$    66,779

$  204,635

$  184,592

General and administrative expense on a GAAP basis

$    62,283

$    52,873

$  187,887

$  159,030

Stock-based compensation expense

(17,508)

(17,333)

(53,109)

(48,083)

Amortization of purchased intangibles

(57)

(57)

(169)

(169)

General and administrative expense on a non-GAAP basis

$    44,718

$    35,483

$  134,609

$  110,778

Operating expense on a GAAP basis

$  320,334

$  277,040

$  935,622

$  796,412

Stock-based compensation expense

(86,679)

(78,324)

(250,102)

(214,722)

Amortization of purchased intangibles

(3,641)

(3,641)

(10,804)

(10,804)

Operating expense on a non-GAAP basis

$  230,014

$  195,075

$  674,716

$  570,886

Operating income on a GAAP basis

$  128,489

$  121,404

$  294,070

$  350,168

Stock-based compensation expense

101,226

93,187

294,840

256,363

Amortization of purchased intangibles

4,906

4,906

14,558

14,558

Operating income on a non-GAAP basis

$  234,621

$  219,497

$  603,468

$  621,089

Operating margin on a GAAP basis

20.8 %

22.0 %

17.0 %

22.0 %

Stock-based compensation expense

16.4

16.9

17.0

16.1

Amortization of purchased intangibles

0.9

0.8

0.8

0.9

Operating margin on a non-GAAP basis

38.1 %

39.7 %

34.8 %

39.0 %

Net income on a GAAP basis

$  135,158

$  108,457

$  378,307

$  299,173

Stock-based compensation expense

101,226

93,187

294,840

256,363

Amortization of purchased intangibles

4,906

4,906

14,558

14,558

Income tax effect on non-GAAP adjustments(6)

(22,612)

(23,306)

(123,070)

(60,817)

Net income on a non-GAAP basis

$  218,678

$  183,244

$  564,635

$  509,277

Diluted net income per share on a GAAP basis

$        0.83

$        0.67

$        2.32

$        1.84

Stock-based compensation expense

0.62

0.57

1.81

1.58

Amortization of purchased intangibles

0.03

0.03

0.09

0.09

Income tax effect on non-GAAP adjustments(6)

(0.14)

(0.14)

(0.76)

(0.37)

Diluted net income per share on a non-GAAP basis

$        1.34

$        1.13

$        3.46

$        3.14

(6)

For the three and nine months October 31, 2023 and 2022, management used an estimated annual effective non-GAAP tax rate of 21.0%.

SOURCE Veeva Systems

Go to Source